DelveInsight’s ‘Complex Regional Pain Syndrome (CRPS) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CRPS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Study Period: 2017–2030
Complex regional pain syndrome (CRPS) is one of the most challenging chronic pain condition that is characterized by progressively worsening spontaneous regional pain without dermatomal distribution. The pain experienced is out of proportion in time and severity to the inciting event and accompanied by symptoms that vary in severity including skin changes, autonomic dysfunction, abnormal sensory and motor changes, and trophic changes. CRPS may develop after major trauma, surgery, or minor injury, and progresses with a variable course that ranges from self-limiting, mild symptomatology to chronic disease. In many cases, disease progression is debilitating and severely limits patients’ quality of life, creating a tremendous burden on patients and their families. Over time, CRPS has been defined and redefined. CRPS develops after an inciting noxious stimulus to an affected limb. There is little agreement with regards to the etiology, symptoms, clinical presentation, diagnosis, or treatment of CRPS.
In order to bring some uniformity to this problem, the International Association for the Study of Pain (IASP) in 1994 introduced the term CRPS to describe a wide variety of post-traumatic neuropathic pain conditions of the limbs. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS. Patients typically progress through three stages —Stage I or acute stage (may last up to 3 months), Stage II or Dystrophic stage (can last 3–12 months), Stage III and atrophic stage (occurs after 1 year). There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.
The CRPS epidemiology division provides the insights about historical and current CRPS patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
In the year 2017, the total prevalent case of CRPS was 310,489 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total prevalent cases of CRPS, Total diagnosed prevalent cases of CRPS, Gender-specific diagnosed prevalent cases of CRPS, Age-specific diagnosed prevalent cases of CRPS, Type-specific diagnosed prevalent cases of CRPS, Severity-specific diagnosed prevalent cases of CRPS, and Total Treated Cases of CRPS scenario of CRPS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CRPS scenario of the indications.
The CRPS Epidemiology report will allow the user to -
1. Key Insights
2. Executive Summary of Complex Regional Pain Syndrome (CRPS)
3. Complex Regional Pain Syndrome (CRPS): Disease Background and Overview
3.1. Introduction
3.2. Symptoms
3.3. Causes
3.4. Outcomes of CRPS
3.5. Clinical presentations
3.6. Natural course of CRPS
3.7. Classification
3.8. Pathophysiology
3.9. Diagnosis
3.9.1. Investigations
3.9.2. Imaging Techniques
3.9.3. Non-invasive imaging techniques
3.9.4. Thermography
3.9.5. Sudomotor Function Tests
3.9.6. Neurophysiological Tests
3.9.7. Examination
3.9.8. Differential diagnosis
3.10. Diagnostic Guidelines for CRPS
3.10.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA
3.10.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
3.10.3. Japanese CRPS diagnostic criteria
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Assumptions and Rationale
4.3. Epidemiology Scenario: 7MM
4.3.1. Total Prevalent Cases of CRPS in the 7MM
4.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM
4.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM
4.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM
4.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in 7MM
4.3.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM
4.3.7. Treated cases of CRPS in the 7MM
4.4. The United States Epidemiology
4.4.1. Total Prevalent Cases of CRPS in the United States
4.4.2. Total Diagnosed Prevalent cases of CRPS in the United States
4.4.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United States
4.4.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United States
4.4.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United States
4.4.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States
4.4.7. Treated cases of CRPS in the United States
4.5. EU-5 Epidemiology
4.6. Germany
4.6.1. Total Prevalent Cases of CRPS in Germany
4.6.2. Total Diagnosed Prevalent cases of CRPS in Germany
4.6.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Germany
4.6.4. Age-specific Diagnosed Prevalent Cases of CRPS in Germany
4.6.5. Type-specific Diagnosed Prevalent Cases of CRPS in Germany
4.6.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany
4.6.7. Treated cases of CRPS in Germany
4.7. France
4.7.1. Total Prevalent Cases of CRPS in France
4.7.2. Total Diagnosed Prevalent cases of CRPS in France
4.7.3. Gender-specific Diagnosed Prevalent Cases of CRPS in France
4.7.4. Age-specific Diagnosed Prevalent Cases of CRPS in France
4.7.5. Type-specific Diagnosed Prevalent Cases of CRPS in France
4.7.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in France
4.7.7. Treated cases of CRPS in France
4.8. Italy
4.8.1. Total Prevalent Cases of CRPS in Italy
4.8.2. Total Diagnosed Prevalent cases of CRPS in Italy
4.8.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Italy
4.8.4. Age-specific Diagnosed Prevalent Cases of CRPS in Italy
4.8.5. Type-specific Diagnosed Prevalent Cases of CRPS in Italy
4.8.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy
4.8.7. Treated cases of CRPS in Italy
4.9. Spain
4.9.1. Total Prevalent Cases of CRPS in Spain
4.9.2. Total Diagnosed Prevalent cases of CRPS in Spain
4.9.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Spain
4.9.4. Age-specific Diagnosed Prevalent Cases of CRPS in Spain
4.9.5. Type-specific Diagnosed Prevalent Cases of CRPS in Spain
4.9.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain
4.9.7. Treated cases of CRPS in Spain
4.10. The United Kingdom
4.10.1. Total Prevalent Cases of CRPS in the United Kingdom
4.10.2. Total Diagnosed Prevalent cases of CRPS in the United Kingdom
4.10.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
4.10.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
4.10.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
4.10.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom
4.10.7. Treated cases of CRPS in the United Kingdom
4.11. Japan Epidemiology
4.11.1. Total Prevalent Cases of CRPS in Japan
4.11.2. Total Diagnosed Prevalent cases of CRPS in Japan
4.11.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Japan
4.11.4. Age-specific Diagnosed Prevalent Cases of CRPS in Japan
4.11.5. Type-specific Diagnosed Prevalent Cases of CRPS in Japan
4.11.6. Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan
4.11.7. Treated cases of CRPS in Japan
5. Appendix
5.1. Bibliography
5.2. Report Methodology
6. DelveInsight Capabilities
7. Disclaimer
8. About DelveInsight
List of Table
Table 1 Summary of CRPS, Epidemiology, and Key Events (2017–2030)
Table 2 Comparison of CRPS Types
Table 3 Common characteristics of CRPS
Table 1 Stages of CRPS
Table 2 IASP clinical diagnostic criteria for CRPS - Budapest Criteria (2012)
Table 3 Difference between CRPS Types
Table 4 Possible mechanisms involved in complex regional pain syndrome
Table 5 Summary of pathophysiologic mechanisms that may contribute to CRPS
Table 6 Differential Diagnosis
Table 7 Technical investigations helpful to exclude a differential diagnosis
Table 8 Differential Diagnosis
Table 9 Levels of evidence
Table 10 Original International Association for the Study of Pain (Orlando) diagnostic criteria for complex regional pain syndrome
Table 11 Factors (and factor loadings) resulting from principal components factor analysis of diagnostic and associated signs and symptoms of CRPS
Table 12 Clinical diagnostic criteria for CRPS
Table 13 Summary of sensitivity and specificity of the clinical and research criteria
Table 14 Diagnosis of CRPS – Recommendations
Table 15 Referral – Recommendations
Table 16 Surgical practice – Diagnostic Recommendations
Table 17 Diagnosis of CRPS in emergency medicine - Recommendations
Table 18 The Veldman criteria
Table 19 Factors (and factor loadings) resulting from factor analysis of CRPS-related signs/symptoms
Table 20 Japanese CRPS diagnostic criteria for clinical purposes
Table 21 Total Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 22 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017–2030)
Table 23 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 24 Age-specific Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 25 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017–2030)
Table 26 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Table 27 Total Treated cases of CRPS in the 7MM (2017–2030)
Table 28 Total Prevalent Cases of CRPS in the United States (2017–2030)
Table 29 Total Diagnosed Prevalent cases of CRPS in the United States (2017–2030)
Table 30 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 31 Age-specific Prevalent Cases of CRPS in the United States (2017–2030)
Table 32 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 33 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Table 34 Total Treated cases of CRPS in the United States (2017–2030)
Table 35 Total Prevalent Cases of CRPS in Germany (2017–2030)
Table 36 Total Diagnosed Prevalent cases of CRPS in Germany (2017–2030)
Table 37 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 38 Age-specific Prevalent Cases of CRPS in Germany (2017–2030)
Table 39 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 40 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Table 41 Total Treated cases of CRPS in Germany (2017–2030)
Table 42 Total Prevalent Cases of CRPS in France (2017–2030)
Table 43 Total Diagnosed Prevalent cases of CRPS in France (2017–2030)
Table 44 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 45 Age-specific Prevalent Cases of CRPS in France (2017–2030)
Table 46 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 47 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Table 48 Total Treated cases of CRPS in France (2017–2030)
Table 49 Total Prevalent Cases of CRPS in Italy (2017–2030)
Table 50 Total Diagnosed Prevalent cases of CRPS in Italy (2017–2030)
Table 51 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 52 Age-specific Prevalent Cases of CRPS in Italy (2017–2030)
Table 53 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 54 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Table 55 Total Treated cases of CRPS in Italy (2017–2030)
Table 56 Total Prevalent Cases of CRPS in Spain (2017–2030)
Table 57 Total Diagnosed Prevalent cases of CRPS in Spain (2017–2030)
Table 58 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 59 Age-specific Prevalent Cases of CRPS in Spain (2017–2030)
Table 60 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 61 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Table 62 Total Treated cases of CRPS in Spain (2017–2030)
Table 63 Total Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 64 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017–2030)
Table 65 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 66 Age-specific Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 67 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017–2030)
Table 68 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Table 69 Total Treated cases of CRPS in the United Kingdom (2017–2030)
Table 70 Total Prevalent Cases of CRPS in Japan (2017–2030)
Table 71 Total Diagnosed Prevalent cases of CRPS in Japan (2017–2030)
Table 72 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 73 Age-specific Prevalent Cases of CRPS in Japan (2017–2030)
Table 74 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 75 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Table 76 Total Treated cases of CRPS in Japan (2017–2030)
List of Figures
Figure 1 CRPS SWOT Analysis
Figure 2 Complex regional pain syndrome - CRPS
Figure 3 Typical features of a patient with CRPS
Figure 4 Causes of CRPS
Figure 5 Model for the development of complex regional pain syndrome (CRPS) from nerve injury
Figure 6 Speculative model of interacting mechanisms involved in the development of CRPS
Figure 7 Total Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 8 Total Diagnosed Prevalent cases of CRPS in the 7MM (2017–2030)
Figure 9 Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 10 Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 11 Type-specific Diagnosed Prevalent Cases of CRPS in 7MM (2017–2030)
Figure 12 Severity-Specific Diagnosed Prevalent Cases of CRPS in the 7MM (2017–2030)
Figure 13 Treated cases of CRPS in the 7MM (2017–2030)
Figure 14 Total Prevalent Cases of CRPS in the United States (2017–2030)
Figure 15 Total Diagnosed Prevalent cases of CRPS in the United States (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 19 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United States (2017–2030)
Figure 20 Treated cases of CRPS in the United States (2017–2030)
Figure 21 Total Prevalent Cases of CRPS in Germany (2017–2030)
Figure 22 Total Diagnosed Prevalent cases of CRPS in Germany (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 24 Age-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 25 Type-specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 26 Severity-Specific Diagnosed Prevalent Cases of CRPS in Germany (2017–2030)
Figure 27 Treated cases of CRPS in Germany (2017–2030)
Figure 28 Total Prevalent Cases of CRPS in France (2017–2030)
Figure 29 Total Diagnosed Prevalent cases of CRPS in France (2017–2030)
Figure 30 Gender-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 31 Age-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 32 Type-specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 33 Severity-Specific Diagnosed Prevalent Cases of CRPS in France (2017–2030)
Figure 34 Treated cases of CRPS in France (2017–2030)
Figure 35 Total Prevalent Cases of CRPS in Italy (2017–2030)
Figure 36 Total Diagnosed Prevalent cases of CRPS in Italy (2017–2030)
Figure 37 Gender-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 39 Type-specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 40 Severity-Specific Diagnosed Prevalent Cases of CRPS in Italy (2017–2030)
Figure 41 Treated cases of CRPS in Italy (2017–2030)
Figure 42 Total Prevalent Cases of CRPS in Spain (2017–2030)
Figure 43 Total Diagnosed Prevalent cases of CRPS in Spain (2017–2030)
Figure 44 Gender-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 46 Type-specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 47 Severity-Specific Diagnosed Prevalent Cases of CRPS in Spain (2017–2030)
Figure 48 Treated cases of CRPS in Spain (2017–2030)
Figure 49 Total Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 50 Total Diagnosed Prevalent cases of CRPS in the United Kingdom (2017–2030)
Figure 51 Gender-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 52 Age-specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 53 Type-specific Diagnosed Prevalent Cases of CRPS in the United kingdom (2017–2030)
Figure 54 Severity-Specific Diagnosed Prevalent Cases of CRPS in the United Kingdom (2017–2030)
Figure 55 Treated cases of CRPS in the United Kingdom (2017–2030)
Figure 56 Total Prevalent Cases of CRPS in Japan (2017–2030)
Figure 57 Total Diagnosed Prevalent cases of CRPS in Japan (2017–2030)
Figure 58 Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 59 Age-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 60 Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 61 Severity-Specific Diagnosed Prevalent Cases of CRPS in Japan (2017–2030)
Figure 62 Treated cases of CRPS in Japan (2017–2030)
